Inhibikase Therapeutics to Present at H.C. Wainwright & Co. Global Life Sciences Virtual Conference

ATLANTA, Mar. 2, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today announced that Milton Werner, Ph.D., Chief Executive Officer of Inhibikase, will present at the H.C. Wainwright & Co. Global Life Sciences Virtual Conference.